EZH2 and thyroid gland carcinoma: In this context, gene editing with CRISPR/Cas9 has identified potential molecular targets for treatment and potential biomarkers for use in thyroid cancer research, such as EZH2 (74), HMGA2 (75), and GPX4 (76).